The CEO has written that he would prefer to have IPIX

New Post Public Reply Private Reply Replies (0) Message Board
Drano lousy.engineer #40349
351
The CEO has written that he would prefer to have IPIX become a royalty company -- they discover and do clinical trials on drugs, then they license them to a Big Pharma. Royalty companies offer great advantages to shareholders, because the company is spared the expense of manufacturing and marketing, but gets shares of the proceeds.

He has followed through on his other statements -- just look at the drugs progressing through clinical trials, at relatively VERY low cost and with NO toxic financing --

HOWEVER -- I would love to see the company market Brilacidin-OM on its own, without a Big Pharma involved.

If ever there were a drug that sells itself, it would be Brilacidin-OM.
Think of these advantages:
• Reduces risk of developing severe OM by half (when compared to all past statistics on OM incidence in head and neck cancers, rather than the very low rate of incidence in our study)
• Oral rinse, not an IV
• No systemic exposure (very important for cancer patients who already have many other drugs in their systems and/or have weakened immune systems because of chemo/radiation)
• Easy to use -- just mix a powder with a certain amount of water (assuming that the company proceeds with developing this, as they stated)
• Easy to carry and store, again assuming powdered formulation. No bulky bottles that might need to be refrigerated after opening.

And, the clincher really:
THERE IS NO OTHER DRUG THAT REDUCES THE INCIDENCE OF SEVERE OM

It would take a very small sales force -- just a couple of people to staff tables at conventions, and to send out brochures -- to market this.
There's no competition, and there are not THAT many oncologists, particularly ones that treat head and neck cancer. It would be easy to contact them all.

What doctor WOULDN'T prescribe Bril-OM, if it reduces the chance of getting a painful and debilitating side effect? Would they want to risk a malpractice suit when the patient developed it, and a nurse in the hospital said "Too bad you didn't use Brilacidin-OM"?

Think of all the TV ads you see for drugs. How hard would it be to make a good, short ad telling people that they can reduce the risk of chemo and radiation side effects, with a simple oral rinse?

So anyway, MY desire would be for the company to go it alone for Bril-OM. The proceeds could fund all the clinical trials they want to do.

But that's not what they've stated as their plan.

Lousy engineer, sorry for such a long response -- if you're still reading....

Innovation Pharmaceuticals Inc (IPIX) Stock Research Links

IPIX Board Company Profile Buy Rating Time & Sales News Filings Financials
Scroll down for more posts ▼

Top 10 Most Recent News Articles

PITAKA Redefines Tech Style With Berlin Launch Event

Updated Category News Views 1

Setting the Stage for Innovation Ah, Berlin in September—a city that’s hardly shy of showcasing avant-garde moves. And this time, we’re not talking about some cryptic art installation or underground techno rave. Nope, it's PITAKA making waves, transforming an edgy display at The Feuerle Collection. You see, on September 5, they unveiled their 'Wind Over Wheat'...

Continue Reading
S&P 500 Shuffle: Bloom, Illumina, Everpure Join Frenzy

Updated Category News Views 5

Index Shuffles Stir Market Pot Changes are afoot, folks, with the movers and shakers of the market indices stepping into the spotlight. A lot is brewing with S&P Dow Jones Indices making significant switches effective September 21, 2026—right before trading heats up. You better believe it's affecting more than a couple of tickers. Who's In and Who's Out? If you’ve...

Continue Reading
Virterion Surges Ahead in VPS Racing With Reliable Hosting

Updated Category News Views 2

Why Virterion Stands Out in 2026 VPS Landscape For anyone knee-deep in the hosting game, you know the market's got more players than a late-night poker round. Virterion, though—that's a name carving out a noticeable niche, and for solid reasons. In 2026, the backdrop's not just speed, it’s about matching technology and support with what ambitious developers need. VPS...

Continue Reading
Hims & Hers Faces Legal Storm Over Alleged Privacy Breaches

Updated Category News Views 1

Legal Storms Brew Over Alleged Privacy Breaches Well, here we go again, folks. Just when you think the waters are calming, Hims & Hers Health, Inc. (NYSE: HIMS) finds itself in the thick of a nasty securities fraud class action lawsuit. Allegedly they've been less than honest with their customers' health info—something about sneaking around with people's sensitive data...

Continue Reading
PureHealth Research Spotlights Simpler Supplement Trends

Updated Category News Views 0

What's Steering the Supplement Ship? Well, if you're paying any attention to the supplement space, you might've noticed something curious: folks are ditching complicated concoctions for good old fashioned simplicity. PureHealth Research, out of Manassas, is throwing the limelight on this trend, where people are handing in their multi-ingredient cocktail for a single...

Continue Reading
LiberNovo Spotlights Ergonomic Seating at Berlin's IFA 2026

Updated Category News Views 0

LiberNovo Sets the Stage at IFA 2026 If you're poking around Berlin this September, the Messe Berlin is the place to be, especially for those keeping tabs on the consumer tech world. LiberNovo, the ergonomic seating company you might not have had on your radar, is out here making noise. They're throwing down the gauntlet with the Maxis Series, promising a better deal for...

Continue Reading
UGREEN's AI Hub: Privacy-First Tech for Smart Homes

Updated Category News Views 1

UGREEN's Big AI Leap In the bustling scene of home tech evolution, UGREEN's throwing its hat in the ring with its latest offerings. They've just rolled out the UGREEN HomeAgent series, aiming to redefine what we think of when it comes to smart living. UGREEN, usually known for its tech gadgets, is diving headfirst into the smart home pool. These local AI hubs blend tech...

Continue Reading
Rho Adds Credit Card Payments to Invoices

Updated Category News Views 2

Rho's New Game: Credit Card Payments on Invoices Ah, the wonderful world where your invoices can finally ride the plastic wave! Rho, that scrappy finance platform everyone's been chattering about, just rolled out a card payment feature. Yep, from credit cards to Google Pay, they’re letting businesses skip the usual financial hurdles and get their dough directly from...

Continue Reading
York Space Systems Faces Class Action Headwinds

Updated Category News Views 4

York Space Systems: Under Legal Fire You ever hear the one about York Space Systems? Yeah, their ticker YSS is buzzing for all the wrong reasons. Not even a year out from their IPO, and already they're tangled in a class action lawsuit that's got investors with their heads in their hands. ClaimsFiler, a shareholder information outfit, just blasted out a reminder for...

Continue Reading
Signant and Lothar Forge Future in Clinical Trials

Updated Category News Views 1

Breathing New Life into Clinical Trials Alright, folks, listen up. We've got a fresh collaboration cooking that could shake things up in the clinical trial sector. Signant Health, a heavyweight in clinical trial solutions, has teamed up with Lothar Medical, and they’ve hitched their wagons to launch something rather intriguing: the ALDS PRO pulmonary function tech. Let...

Continue Reading

Top 5 Most Recently Viewed Articles

Rover's Insightful Report on Pet Parenthood Cost Trends

Updated Category News Views 209

Understanding the True Cost of Pet Parenthood In their sixth annual report, Rover, a leading online marketplace for pet care, dives deep into the financial aspects of owning pets, highlighting significant trends among pet parents in Canada. This insightful report reveals how pet owners are adapting to a rapidly changing environment, particularly in light of new tariffs...

Continue Reading
Blink Charging Unveils Insights on EV Trends in Live Chat

Updated Category News Views 81

What to Expect from Blink’s Upcoming EV Conversation On September 12 at 10 AM E.T., Brendan Jones and Michael Battaglia will sit down for a live fireside chat—the first such discussion since Blink announced leadership changes planned for 2025. It’s a timely moment to hear directly from the team about how the electric vehicle (EV) landscape is shifting and where...

Continue Reading
MaxLinear's Innovative AI Framework Enhances Wi-Fi for Users

Updated Category News Views 167

MaxLinear Reveals New MaxAI Framework for Enhanced Wi-Fi MaxLinear, Inc. (Nasdaq: MXL), a leader in broadband access technology, has unveiled its revolutionary MaxAI framework. Designed to enhance user experiences and reduce operational costs for Multiple System Operators (MSOs), this native machine learning (ML) technology promises to address the modern challenges faced...

Continue Reading
Breakthrough Publication Highlights Phase 1 Findings of Rhenium-186 Re in Glioblastoma Treatment

Updated Category News Views 138

Exciting Developments in Glioblastoma Treatment Recent advances in the treatment of glioblastoma have emerged, particularly with the promising findings highlighted in a peer-reviewed publication featuring Rhenium-186 Obisbemeda. This innovative approach shows valuable potential for enhancing treatment outcomes for patients suffering from this aggressive form of brain...

Continue Reading
Peter Schiff Warns of Impending Bitcoin and MSTR Collapse

Updated Category News Views 146

Peter Schiff's Bold Predictions for Bitcoin and MSTR Peter Schiff, a prominent financial commentator, has once again made headlines in the cryptocurrency world with his insightful analysis of Bitcoin. His recent statements on social media have raised eyebrows, particularly regarding the future of both Bitcoin and MicroStrategy (NASDAQ: MSTR), a key player in the crypto...

Continue Reading